{
    "2019-08-23": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Will Lawsuits Sink Johnson & Johnson Stock?",
                "features": {
                    "keywords": [
                        "lawsuits",
                        "Johnson & Johnson",
                        "stock"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Phase 3",
                        "Baricitinib",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Arbitration panel rules in favor of Lilly in complaint filed by Adocia",
                "features": {
                    "keywords": [
                        "Arbitration",
                        "Lilly",
                        "Adocia"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Roxadustat",
                        "China"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}